[Problems in drug prevention and treatment of endogenous infection and dysbacteriosis].
Dysbacteriosis is an important pathogenetic condition in the development of endogenous infection whose treatment and prevention are among the most topical and challenging problems. The common cause of dysbacteriosis is antibiotic therapy and prevention of surgical infection. Antibiotic therapy should be performed in accordance to strict indications, with compliance of rational regimens and methods for using drugs. Adequate local and parenteral drugs should be given in wound infection. To prevent endogenous infection, selective gastrointestinal decontamination (SD) that requires bacteriological surveillance of the patient's intestinal microflora and the environment, as well as the use of eubiotics. In critically ill patients with multiple injuries, in patients on artificial pulmonary ventilation, other individuals at risk SD is highly effective, in which oral of intragastric antibiotics which are intestinally unabsorbable and active against only anaerobic opportunistic microbes were added by the same agents for the oral cavity and by lactic acid bifidumbacterin. The new biological drug Bifilys that contains the optimum balanced ratio of bifidobacteria and lysozyme and provides a prompt correction of microbiocenosis, local immunity, and intestinal function is highly effective in the treatment and prevention of dysbacteriosis. Electrochemically activated solutions are also promising in treating dysbacteriosis and digestive infections. There are available original Russian antiviral synthetic and natural agents to make drug therapy and prevention of viral infections frequently complicating the status of weak patients.
Melńikova
V M
VM
TsITO of NN Priorov, Moscow.
Belikov
G P
GP
Shcherbakova
E G
EG
Blatun
L A
LA
Rastunova
G A
GA
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis / Q000009:adverse effects; D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D001424:Bacterial Infections / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control*; D003131:Combined Modality Therapy; D004064:Digestive System / Q000382:microbiology*; D005767:Gastrointestinal Diseases / Q000150:complications* / Q000628:therapy; D006801:Humans; D012307:Risk Factors
D000900:Anti-Bacterial Agents